Meeting
2023 ASCO Breakthrough
Her-2 promoting tumor progression and cisplatin resistance as a novel therapeutic target in penile squamous cell carcinoma.
Authors
Xingliang Tan
Sun Yat-Sen University Cancer Center, Guangzhou, China
Xingliang Tan , Kai Yao
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Breast Cancer,Central Nervous System Tumors,Developmental Therapeutics,Genitourinary Cancer,Hematologic Malignancies,Thoracic Cancers,Other Malignancies or Topics
Sub Track
Antibody Drug Conjugates
Citation
JCO Global Oncology 9, 2023 (suppl 1; abstr 67)
DOI
10.1200/GO.2023.9.Supplement_1.67
Abstract #
67
Poster Bd #
D3
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Clinical outcome according to tumor HER2 status and EGFR expression in advanced gastric cancer patients from the EXPAND study.
First Author: Florian Lordick
Poster
2011 ASCO Annual Meeting
Prognostic significance of human epidermal growth factor-2 (HER2) in advanced gastric cancer: A U.S. and European international collaborative analysis.
First Author: M. A. Shah
Poster
2024 ASCO Breakthrough
Differences in the expression heterogeneity of ADC-related markers between primary tumors and metastatic lymph nodes in advanced urothelial cancers.
First Author: Xingliang Tan
Poster
2024 ASCO Annual Meeting
SAVE: A prospective, single-arm, single-center clinical study of disitamab vedotin in combination with toripalimab in patients with advanced penile cancer that has progressed or is intolerant to cisplatin chemotherapy.
First Author: Fang Yuan